Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Afzelin inhibits migration of MDA-MB-231 cells by suppressing FAK expression and Rac1 activation

Eva Rachmi, Basuki Bambang Purnomo, Agustina Tri Endharti, Loeki Enggar Fitri.




Abstract

Triple-negative breast cancer (TNBC) has the worst prognosis and the most incidence of metastatic among other types of breast cancer. These characteristics are supported by dysregulation of FAK and RAC1 which are the key player of mesenchymal cell migration on TNBC. Afzelin is a secondary metabolite that contained in the variety of plants. This study explored the anti-migration effect of afzelin and its interaction with FAK and Rac1 on the highly invasive TNBC cell line, MDA-MB-231. Cell viability was assessed by MTT assay and cell migration was evaluated using in vitro scratch assay. Rac1 activation was analyzed using the colorimetric assay, while vinculin and actin filaments were stained using immunofluorescent. The quantity of total FAK and phosphorylated FAK tyr397 was detected by Western blotting. Afzelin decreased cell viability and inhibited two-dimensional cell migration in a dose-dependent manner. Under CLMS, vinculin localization at the cell edge demonstrated reduction of focal adhesion formation by afzelin. Further exploration showed that afzelin decreased FAK expression but did not affect FAK phosphorylation at tyr397. In addition, afzelin decreased Rac1-GTPase activation, which is a downstream effector of FAK. Taken together, these results suggest that afzelin suppresses TNBC cell migration, through inhibition of FAK expression and Rac1-GTPase activation.

Key words: Afzelin, TNBC, cell migration, FAK, Rac1






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.